Financial Performance - For the six months ended June 30, 2021, the Group's total revenue was approximately HK$471.3 million, representing an increase of approximately 60.7% compared to HK$293.3 million for the same period last year[7]. - The Group recorded a gross profit of approximately HK$103.4 million, with a gross profit margin of approximately 21.9%, compared to a gross profit of HK$68.7 million and a margin of 23.4% in the previous year[7]. - Profit attributable to equity holders for the six months ended June 30, 2021, was approximately HK$39.2 million, a significant increase from HK$5.6 million in the same period last year[7]. - Basic earnings per share attributable to equity holders were approximately 6.32 HK cents, compared to 0.90 HK cents for the same period last year[7]. - Total comprehensive income for the period was HK$46,186,000, compared to a loss of HK$5,940,000 in the previous year[84]. - The company reported a profit for the period of HK$39,197,000 for the six months ended June 30, 2021, compared to a profit of HK$5,556,000 for the same period in the previous year, indicating a significant increase[92]. - The basic earnings per share for the six months ended June 30, 2021, was HK$6.32, compared to HK$0.90 for the same period in 2020, reflecting a substantial increase of 600%[160]. Revenue Segments - The growth in revenue was primarily driven by increased sales in the e-cigarette products and integrated plastic solutions segments[7]. - The e-cigarettes products segment revenue for the six months ended June 30, 2021, was approximately HK$280.3 million, accounting for approximately 59.5% of total revenue, and representing an increase of approximately HK$107.9 million, or approximately 62.6%, from approximately HK$172.4 million for the same period in 2020[19]. - The integrated plastic solutions segment revenue for the six months ended June 30, 2021, was approximately HK$189.8 million, accounting for approximately 40.3% of total revenue, and representing an increase of approximately HK$73.7 million, or approximately 63.5%, from approximately HK$116.1 million for the same period in 2020[18]. - The medical consumable products segment revenue for the six months ended June 30, 2021, was approximately HK$1.2 million, accounting for approximately 0.2% of total revenue, and representing a decrease of approximately HK$3.5 million, or approximately 74.5%, from approximately HK$4.7 million for the same period in 2020[20]. Cost and Expenses - Selling and distribution costs for the six months ended June 30, 2021, were approximately HK$3.5 million, a decrease of approximately 32.7% from HK$5.2 million in the same period of 2020[26]. - Administrative and other operating expenses for the six months ended June 30, 2021, were approximately HK$54.9 million, unchanged from the same period in 2020[26]. - Finance costs for the six months ended June 30, 2021, were approximately HK$4.3 million, similar to HK$4.5 million for the same period in 2020[26]. - Research and development expenses totaled HK$12,162,000, reflecting the company's commitment to innovation and product development[119]. - Staff costs, including directors' emoluments, rose to HK$73,795,000 for the six months ended June 30, 2021, compared to HK$48,085,000 in 2020, marking an increase of 53.4%[149]. Assets and Liabilities - As of June 30, 2021, the Group had bank balances and cash of approximately HK$63.9 million, down from HK$117.0 million as of December 31, 2020[30]. - Interest-bearing borrowings as of June 30, 2021, amounted to HK$210.5 million, with a weighted average effective interest rate of approximately 3.02% per annum[30]. - The Group's gearing ratio as of June 30, 2021, was 39.7%, a decrease from 44.5% as of December 31, 2020[30]. - Net current liabilities increased to approximately HK$64.1 million as of June 30, 2021, up by approximately HK$15.4 million from HK$48.7 million as of December 31, 2020[30]. - Non-current assets increased to HK$794,773,000 as of June 30, 2021, from HK$755,849,000 at the end of 2020[86]. - The total trade and other receivables as of June 30, 2021, amounted to HK$216,642,000, compared to HK$188,828,000 as of December 31, 2020, marking an increase of about 14.7%[190]. Market and Product Development - The Group distributes its medical consumable products, including disposable face masks, under its own brand "CAREWE" to both domestic and overseas markets[7]. - The Group has developed higher-level protection face masks, such as KN95 and FFP2, which have passed relevant standards and certifications[21]. - The Group plans to continue expanding its e-cigarette product line and integrated plastic solutions to capture a larger market share in the upcoming quarters[135]. Corporate Governance - The Company has complied with the Corporate Governance Code during the six months ended 30 June 2021[50]. - The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2021 (30 June 2020: Nil)[55]. - All Directors confirmed compliance with the Model Code for Securities Transactions during the six months ended 30 June 2021[55]. Shareholder Information - As of 30 June 2021, Mr. Chan Tsan Lam holds a total interest of 379,923,000 shares, representing approximately 61.3% of the Company[60]. - The total number of shares held by substantial shareholders reflects significant ownership concentration within the company[68]. - The Company granted 37,840,000 share options to eligible participants on May 13, 2020, which resulted in potential dilutive ordinary shares being recognized[171].
天长集团(02182) - 2021 - 中期财报